tissue, disease associated with dysregulation of the HGF/c-met signaling axis, the proliferative and/or the cancer is characterized by c-met expression or activity. In some embodiments, c-met expression is c-met over-expression.

[0037] In addition, provided herein are articles of manufacture comprising a container with a composition, lot, or pharmaceutical formulation described above contained therein. Further provided herein are methods of making the article of manufacture.

[0038] ~~Provided herein is~~In one aspect, there is provided a composition comprising an anti-c-met antibody, wherein host cell protein (HCP) is present in less than or equal to about 50 ng/mg, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0039] In one aspect, there is provided~~Also provided herein is~~ a composition comprising an anti-c-met antibody, wherein HCP is present in less than or equal to about 50 ng/mg, the DNA levels in the composition comprising an anti-c-met antibody are less than or equal to about 0.3 pg/mg, the LpA in the composition comprising an anti-c-met antibody is less than or equal to about 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition comprising an anti-c-met antibody is less than or equal to about 0.01 EU/mg, the percentage of aggregates in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of monomer in the composition comprising an anti-c-met antibody is greater than or equal to about 99.5%, the percentage of fragments in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of acidic variants in the composition comprising an anti-c-met antibody is less than or equal to about 20%, the percentage of main peak in the composition comprising an anti-c-met antibody is greater than or equal to about 75%, and the percentage of basic variants in the composition comprising an anti-c-met antibody is less than or equal to about 2.0%, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0040] In one aspect, there is provided~~Also provided herein is~~ a composition comprising an anti-c-met antibody, wherein HCP is present in less than or equal to about 15 ng/mg, the DNA levels in the composition comprising an anti-c-met antibody are less than or equal to about 0.3 pg/mg, the LpA in the composition comprising an anti-c-

met antibody is less than or equal to about 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition comprising an anti-c-met antibody is less than or equal to about 0.01 EU/mg, the percentage of aggregates in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of monomer in the composition comprising an anti-c-met antibody is greater than or equal to about 99.5%, the percentage of fragments in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of acidic variants in the composition comprising an anti-c-met antibody is less than or equal to about 20%, the percentage of main peak in the composition comprising an anti-c-met antibody is greater than or equal to about 75%, and the percentage of basic variants in the composition comprising an anti-c-met antibody is less than or equal to about 2.0%, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0041] In one aspect, there is provided~~Also provided herein is~~ a method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of greater than 28°C and a pH between about pH 6 and about pH 8 for more than 6 hours, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex. In some embodiments, the method further comprises centrifuging the composition comprising the anti-c-met antibody. In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on MabSelect SuRe resin and eluting the anti-c-met antibody.

[0042] In one aspect, there is provided~~Also provided herein is~~ a method of purifying an anti-c-met antibody comprising loading a composition comprising an anti-c-met antibody on MabSelect SuRe resin and eluting the anti-c-met antibody, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a

Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0043] In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through. In some embodiments, the weak anion exchange resin is run in flow-through mode.

[0044] In one aspect, there is provided ~~Also provided herein is~~ a method of purifying an anti-c-met antibody comprising loading a composition comprising an anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex. In some embodiments, the weak anion exchange resin is run in flow-through mode.

[0045] In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on a strong cation exchange resin and eluting the anti-c-met antibody. In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on a strong anion exchange resin and eluting the anti-c-met antibody. In some embodiments, the method further comprises ultrafiltering and/or diafiltering the composition comprising the anti-c-met antibody.

[0046] In one aspect, there is provided ~~Also provided herein is~~ a composition comprising an anti-c-met antibody purified or obtainable by any of the methods ~~of claims 4-14~~ as defined above, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0046a] In one aspect, there is provided a pharmaceutical formulation comprising the composition as defined above.

[0046b] In one aspect, there is provided use of the pharmaceutical formulation as defined above in the manufacture of a medicament for inhibiting c-met activated cell proliferation, wherein the medicament is to be contacted with a cell or tissue.

[0046c] In one aspect, there is provided use of the pharmaceutical formulation as defined above in the manufacture of a medicament for modulating a disease associated with dysregulation of the HGF/c-met signaling axis in a subject.

[0046d] In one aspect, there is provided use of the pharmaceutical formulation as defined above in the manufacture of a medicament for treating a subject having a proliferative disorder.

[0046e] In one aspect, there is provided an article of manufacture comprising a container with the pharmaceutical formulation as defined above contained therein.

[0046f] In one aspect, there is provided a method of making the article of manufacture as defined above.

[0046g] In one aspect, there is provided an *in vitro* method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation as defined above.

[0047] In some embodiments of the compositions of the ~~invention~~disclosure, host cell protein (HCP) is present in less than or equal to about 50 ng/mg. In some embodiments, the HCP is present in between about 1 ng/mg and 15 ng/mg. In some embodiments, the HCP is *E. coli* protein (ECP).

[0048] In some embodiments of the composition and methods of the ~~invention~~disclosure, the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPN FKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPN FKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19) and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).

20. The composition or method of claim 19, wherein the Fc region increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.

21. The composition or method of any one of claims 1-20, wherein the first Fc polypeptide comprises the Fc sequence depicted in Figure 1 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in Figure 2 (SEQ ID NO: 18).

22. The composition or method of any one of claims 1-21, wherein the anti-c-met antibody is onartuzumab.

23. The composition or method of any one of claims 1-22, wherein the anti-c-met antibody binds the same epitope as onartuzumab.

24. The composition or method of any one of claims 1-23, wherein the anti-c-met antibody has a pI of between about 8.0 and about 8.5.

25. A pharmaceutical formulation comprising the composition of any one of claims 1-3 or 15-24.

26. ~~A method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount~~Use of the pharmaceutical formulation of claim 25 in the manufacture of a medicament for inhibiting c-met activated cell proliferation, wherein the medicament is to be contacted with a cell or tissue.

27. ~~A method of modulating a disease associated with dysregulation of the HGF/c-met signaling axis, said method comprising administering to a subject an effective amount~~Use of the pharmaceutical formulation of claim 25 in the manufacture of a medicament for modulating a disease associated with dysregulation of the HGF/c-met signaling axis in a subject.

28. ~~A method of treating a subject having a proliferative disorder, said method comprising administering to the subject an effective amount~~Use of the pharmaceutical formulation of claim 25 in the manufacture of a medicament for treating a subject having a proliferative disorder.

29. The ~~method~~ use of claim 28, wherein the proliferative disorder is cancer.

30. The ~~method~~ use of claim 29, wherein the cancer is lung cancer, glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.

31. The ~~method~~ use of any one of claims 26-30, wherein the medicament further ~~comprising administering~~comprises a second therapeutic agent.

32. An article of manufacture comprising a container with the pharmaceutical formulation of claim 25 contained therein.

33. A method of making the article of manufacture of claim 32.

34. An *in vitro* method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation of claim 25.

35. The method of claim 34, further comprising administering a second therapeutic agent.